JMP Securities Reiterates “Market Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX)
JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $58.00 price target on the stock. PTGX has been the topic of a number of other reports. JPMorgan Chase & Co. increased their price objective on […]
JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $58.00 price target on the stock. PTGX has been the topic of a number of other reports. JPMorgan Chase & Co. increased their price objective on […]
